drugset / Trial / NCT00359476

A Study of Vinflunine in Patients With Gastric Cancer

NCT00359476

Phase 2/3 Terminated 55 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer in patients with advanced or metastatic stomach cancer who have progressed on a prior treatment with a fluoropyrimidine or taxane-containing chemotherapy regimen. The safety of this treatment will also be studied.

Timeline

Start
2007-03
Primary completion
2007-10
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinflunine Small molecule 280 mg/m2 Intravenous
Subject Vinflunine Small molecule 320 mg/m2 Intravenous

Indications